There have been two Patented Medicines (Notice of Compliance) Regulations  (PMNOC Regulations) decisions on the merits so far in 2019 and a pair of appeal decisions: (i) Pfizer was successful in Apotex and Teva’s appeals regarding the validity of a patent claiming Form I o-desmethyl-venlafaxine (ODV)  succinate  (Pfizer’s PRISTIQ); (ii) Valeant was successful against Generic Partners Canada, which alleged invalidity of Valeant’s patent for a controlled-release dosage form of metformin  (Valeant’s GLUMETZA); and (iii) Apotex was successful in its obviousness and claim overbreadth allegations relating to Servier’s patent claiming the arginine salt of perindopril and its hydrates in connection with Apotex’s perindopril arginine/amlodipine product (Servier’s VIACORAM).

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.